Portal de Periódicos da CAPES

Iron as a therapeutic target for Parkinson's disease

2018; Wiley; Volume: 33; Issue: 4 Linguagem: Inglês

10.1002/mds.27275

1531-8257

Caroline Moreau, James A. Duce, Olivier Rascol, Jean‐Christophe Devedjian, Daniela Berg, David T. Dexter, Zvi-Ioav Cabantchik, Ashley I. Bush, David Devos,

Trace Elements in Health

Movement DisordersVolume 33, Issue 4 p. 568-574 Viewpoint Iron as a therapeutic target for Parkinson's disease Caroline Moreau MD, PhD, Caroline Moreau MD, PhD orcid.org/0000-0002-5683-2709 Université de Lille, CHU de Lille, INSERM UMRS_1171, Service de Neurologie NS-Park/FCRIN Network LICEND COEN Center, Lille, FranceSearch for more papers by this authorJames A. Duce PhD, James A. Duce PhD School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, West Yorkshire, UK, and Oxidation Biology Unit, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, AustraliaSearch for more papers by this authorOlivier Rascol MD, PhD, Olivier Rascol MD, PhD Université de Toulouse, UPS, CHU de Toulouse, INSERM; Centre d'Investigation Clinique CIC1436, Services de Neurologie et de Pharmacologie Clinique, UMR TONIC, NS-Park/FCRIN Network, NeuroToul COEN Center, Toulouse, FranceSearch for more papers by this authorJean-Christophe Devedjian PhD, Jean-Christophe Devedjian PhD University de Lille, CHU de Lille, INSERM UMRS_1171, NS-Park/FCRIN Network LICEND COEN Center, Lille, FranceSearch for more papers by this authorDaniela Berg MD, PhD, Daniela Berg MD, PhD Department of Neurology, Christian-Albrechts-University of Kiel, Kiel, Germany and Hertie-Institute of Clinical Brain Research, Department of Neurodegeneration, Tübingen, GermanySearch for more papers by this authorDavid Dexter MD, PhD, David Dexter MD, PhD Imperial College London, London, UKSearch for more papers by this authorZ. Ioav Cabantchik PhD, Z. Ioav Cabantchik PhD Della Pergola Chair, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, IsraelSearch for more papers by this authorAshley I. Bush MD, PhD, Ashley I. Bush MD, PhD Oxidation Biology Unit, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, AustraliaSearch for more papers by this authorDavid Devos MD, PhD, Corresponding Author David Devos MD, PhD david.devos@chru-lille.fr orcid.org/0000-0002-2417-799X Université de Lille, CHU de Lille, INSERM UMRS_1171, Service de Pharmacologie Clinique et Service de Neurologie NS-Park/FCRIN Network LICEND COEN Center, Lille, FranceCorrespondence to: David Devos, MD, PhD, Département de Pharmacologie Médicale, Université Lille INSERM 1171, CHU de Lille, F-59037 Lille, France; E-mail: david.devos@chru-lille.frSearch for more papers by this authorthe FAIRPARK-II study group, the FAIRPARK-II study groupSearch for more papers by this author Caroline Moreau MD, PhD, Caroline Moreau MD, PhD orcid.org/0000-0002-5683-2709 Université de Lille, CHU de Lille, INSERM UMRS_1171, Service de Neurologie NS-Park/FCRIN Network LICEND COEN Center, Lille, FranceSearch for more papers by this authorJames A. Duce PhD, James A. Duce PhD School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, West Yorkshire, UK, and Oxidation Biology Unit, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, AustraliaSearch for more papers by this authorOlivier Rascol MD, PhD, Olivier Rascol MD, PhD Université de Toulouse, UPS, CHU de Toulouse, INSERM; Centre d'Investigation Clinique CIC1436, Services de Neurologie et de Pharmacologie Clinique, UMR TONIC, NS-Park/FCRIN Network, NeuroToul COEN Center, Toulouse, FranceSearch for more papers by this authorJean-Christophe Devedjian PhD, Jean-Christophe Devedjian PhD University de Lille, CHU de Lille, INSERM UMRS_1171, NS-Park/FCRIN Network LICEND COEN Center, Lille, FranceSearch for more papers by this authorDaniela Berg MD, PhD, Daniela Berg MD, PhD Department of Neurology, Christian-Albrechts-University of Kiel, Kiel, Germany and Hertie-Institute of Clinical Brain Research, Department of Neurodegeneration, Tübingen, GermanySearch for more papers by this authorDavid Dexter MD, PhD, David Dexter MD, PhD Imperial College London, London, UKSearch for more papers by this authorZ. Ioav Cabantchik PhD, Z. Ioav Cabantchik PhD Della Pergola Chair, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, IsraelSearch for more papers by this authorAshley I. Bush MD, PhD, Ashley I. Bush MD, PhD Oxidation Biology Unit, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, AustraliaSearch for more papers by this authorDavid Devos MD, PhD, Corresponding Author David Devos MD, PhD david.devos@chru-lille.fr orcid.org/0000-0002-2417-799X Université de Lille, CHU de Lille, INSERM UMRS_1171, Service de Pharmacologie Clinique et Service de Neurologie NS-Park/FCRIN Network LICEND COEN Center, Lille, FranceCorrespondence to: David Devos, MD, PhD, Département de Pharmacologie Médicale, Université Lille INSERM 1171, CHU de Lille, F-59037 Lille, France; E-mail: david.devos@chru-lille.frSearch for more papers by this authorthe FAIRPARK-II study group, the FAIRPARK-II study groupSearch for more papers by this author First published: 30 January 2018 https://doi.org/10.1002/mds.27275Citations: 72 Caroline Moreau and James A. Duce contributed equally to this study. Relevant conflicts of interests/financial disclosure: : The authors have no financial disclosures to make or potential conflicts of interest to report in relation to this study. Funding agencies: : This article refers to an academic study in progress with the French NS-Park network, which is funded by a grant from the European Commission Horizon 2020 PHC13 2014-2015 (633190): "Conservative iron chelation as a disease-modifying strategy in Parkinson's disease: a multicentre, parallel-group, placebo-controlled, randomized clinical trial of deferiprone (FAIR-PARK-II)"; protocol ID 2015_22; clinical trial: NCT02655315; http://fairpark2.eu. ApoPharma provided deferiprone and advice on the molecule. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Citing Literature Volume33, Issue4Special Issue: Mild Cognitive Impairment in Parkinson's Disease: Not so MildApril 2018Pages 568-574 RelatedInformation